Potential Role of Monocyte Chemoattractant Protein-1 in Monitoring Disease Progression and Response to Treatment in Overactive Bladder Patients
Open Access
- 1 December 2020
- journal article
- research article
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 24 (4), 341-348
- https://doi.org/10.5213/inj.2040366.183
Abstract
Purpose: To compare urinary levels of monocyte chemoattractant protein-1 (MCP-1), an inflammatory cytokine, in healthy controls and overactive bladder (OAB) patients, to correlate changes in urinary MCP-1 with OAB treatment response and symptom severity, and to study the diagnostic potential of MCP-1 for OAB, as well as the efficacy of MCP-1 as a potential biomarker for different phenotypes of OAB. Methods: We used enzyme-linked immunosorbent assay to measure normalized urinary MCP-1 levels in 56 individuals (43 OAB patients and 13 controls). We assessed the OAB patients at 3 visits with 2 validated symptom severity questionnaires (OAB-V8 and Patient Perception of Bladder Condition). Results: The mean pretreatment urinary MCP-1 level at visit 1 (229.2-pg/mg creatinine) was significantly greater than the MCP-1 levels at visit 3 in both the treatment (107.0-pg/mg creatinine) (P <0.001) and control (52.35-pg/mg creatinine) groups (P 30%, whereas nonresponders displayed no significant MCP-1 decrease (P = 0.164). The receiver operating characteristic analysis of the OAB visit 1 and control groups produced an area under the curve of 0.891. We found no significant differences in sex, race, or age between the OAB and control groups. Conclusions: MCP-1 levels differed significantly between the control and OAB groups and were closely correlated with symptom severity and treatment response. The good diagnostic accuracy of MCP-1 for OAB suggests the potential usage of MCP-1 for OAB diagnosis. The varying response of urinary MCP-1 levels to treatment may indicate at least 2 potential phenotypes of OAB. MCP-1, in combination with other biomarkers and symptom severity questionnaires, could potentially aid in developing a patient-centered OAB treatment approach.Funding Information
- National Center for Research Resources
- National Center for Advancing Translational Sciences
- National Institutes of Health (UL1 TR001414)
This publication has 27 references indexed in Scilit:
- Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic TherapyPLOS ONE, 2013
- Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladderInternational Urology and Nephrology, 2013
- Recruitment of Bone Marrow Derived Cells to the Bladder After Bladder Outlet ObstructionJournal of Urology, 2009
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1α as Possible Biomarkers for the Chronic Pelvic Pain SyndromeJournal of Urology, 2008
- The concept of neurogenic inflammationBJU International, 2008
- Nerve Growth Factor and Prostaglandins in the Urine of Female Patients With Overactive BladderJournal of Urology, 2006
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- A YAC Contig of the Human CC Chemokine Genes Clustered on Chromosome 17q11.2Genomics, 1996
- Molecular cloning of gene sequences regulated by platelet-derived growth factorCell, 1983